Evidence map›Paper›PMID 37338298›Full record

ArticlemBio2023

A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance.

Samantha L Grimes, Young J Choi, Anoosha Banerjee, Gabriel Small, Jordan Anderson-Daniels, Jennifer Gribble, Andrea J Pruijssers, Maria L Agostini, Alexandra Abu-Shmais, Xiaotao Lu and 3 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Human coronaviruses: activation and antagonism of innate immune responses.Microbiology and molecular biology reviews : MMBR · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Plausible mechanism of drug resistance and side-effects of COVID-19 therapeutics: a bottleneck for its eradication.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024
    Review
  14. COVID-19 therapeutics.Clinical microbiology reviews · 2024
    Review
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Samantha L GrimesDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center , Nashville, Tennessee, USA.ORCID 0000-0003-1124-2956
Young J ChoiLaboratory of Molecular Biophysics, The Rockefeller University , New York, New York, USA.ORCID 0000-0001-9902-2979
Anoosha BanerjeeLaboratory of Molecular Biophysics, The Rockefeller University , New York, New York, USA.
Gabriel SmallLaboratory of Molecular Biophysics, The Rockefeller University , New York, New York, USA.
Jordan Anderson-DanielsDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center , Nashville, Tennessee, USA.
Jennifer GribbleDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center , Nashville, Tennessee, USA.
Andrea J PruijssersDepartment of Pediatrics, Vanderbilt University Medical Center , Nashville, Tennessee, USA.
Maria L AgostiniDepartment of Pediatrics, Vanderbilt University Medical Center , Nashville, Tennessee, USA.
Alexandra Abu-ShmaisDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center , Nashville, Tennessee, USA.
Xiaotao LuDepartment of Pediatrics, Vanderbilt University Medical Center , Nashville, Tennessee, USA.
Seth A DarstLaboratory of Molecular Biophysics, The Rockefeller University , New York, New York, USA.
Elizabeth CampbellLaboratory of Molecular Biophysics, The Rockefeller University , New York, New York, USA.
Mark R DenisonDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center , Nashville, Tennessee, USA.ORCID 0000-0002-9275-4330
Vanderbilt University Medical Center · USRockefeller University · USVanderbilt Health · US

Funding

Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoVR01AI132178 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, SHEAHAN, TIMOTHY PATRICK · 2017 to 2021
$7.0M
Determinants of Coronavirus Fidelity in Replication and PathogenesisR01AI108197 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BARIC, RALPH S, DENISON, MARK R · 2013 to 2022
$6.5M
Structure, function, and inhibition of the SARS-CoV-2 replication-transcription complexR01AI161278 · NIAID · ROCKEFELLER UNIVERSITY · PI Seth A. Darst · 2021 to 2026
$3.9M
HHS | National Institutes of Health (NIH) R01-AI123178, R01-AI123178S1HHS | National Institutes of Health (NIH) R01-AI161278HHS | National Institutes of Health (NIH) T32AI11254NIAID NIH HHS R01 AI108197NIAID NIH HHS R01 AI132178NIAID NIH HHS R01 AI161278
6 · The paper itself

Abstract

Coronaviruses (CoVs) encode nonstructural proteins 1-16 (nsps 1-16) which form replicase complexes that mediate viral RNA synthesis. Remdesivir (RDV) is an adenosine nucleoside analog antiviral that inhibits CoV RNA synthesis. RDV resistance mutations have been reported only in the nonstructural protein 12 RNA-dependent RNA polymerase (nsp12-RdRp). We here show that a substitution mutation in the nsp13-helicase (nsp13-HEL A335V) of the betacoronavirus murine hepatitis virus (MHV) that was selected during passage with the RDV parent compound confers partial RDV resistance independently and additively when expressed with co-selected RDV resistance mutations in the nsp12-RdRp. The MHV A335V substitution did not enhance replication or competitive fitness compared to WT MHV and remained sensitive to the active form of the cytidine nucleoside analog antiviral molnupiravir (MOV). Biochemical analysis of the SARS-CoV-2 helicase encoding the homologous substitution (A336V) demonstrates that the mutant protein retained the ability to associate with the core replication proteins nsps 7, 8, and 12 but had impaired helicase unwinding and ATPase activity. Together, these data identify a novel determinant of nsp13-HEL enzymatic activity, define a new genetic pathway for RDV resistance, and demonstrate the importance of surveillance for and testing of helicase mutations that arise in SARS-CoV-2 genomes. IMPORTANCE Despite the development of effective vaccines against COVID-19, the continued circulation and emergence of new variants support the need for antivirals such as RDV. Understanding pathways of antiviral resistance is essential for surveillance of emerging variants, development of combination therapies, and for identifying potential new targets for viral inhibition. We here show a novel RDV resistance mutation in the CoV helicase also impairs helicase functions, supporting the importance of studying the individual and cooperative functions of the replicase nonstructural proteins 7-16 during CoV RNA synthesis. The homologous nsp13-HEL mutation (A336V) has been reported in the GISAID database of SARS-CoV-2 genomes, highlighting the importance of surveillance of and genetic testing for nucleoside analog resistance in the helicase.

Indexed as

COVID-19Murine hepatitis virusAdenosine MonophosphateAlanineAnimalsAntiviral AgentsCOVID-19 Drug TreatmentCOVID-19 VaccinesHumansMiceMutationNucleosidesRNARNA-Dependent RNA PolymeraseSARS-CoV-2Viral Nonstructural ProteinsAdenosine MonophosphateAlanineAntiviral AgentsCOVID-19 VaccinesNucleosidesremdesivirRNARNA-Dependent RNA PolymeraseViral Nonstructural Proteinsantiviral resistancecoronavirushelicasemolnupiravirmurine hepatitis virus (MHV)nsp13nucleoside analog inhibitorsremdesivirreplicaseSARS-CoV-2viral fitness

Identifiers

PMID37338298
PMCPMC10470589
OpenAlexW4381309310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.